Literature DB >> 2832782

Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67.

P Zuber1, M F Hamou, N de Tribolet.   

Abstract

Ki-67 is a monoclonal antibody directed against a nuclear antigen present only in proliferating cells in the G1, S, G2, and M phases of the cell cycle. Fifty-one frozen glioma specimens were stained with Ki-67 using the avidin-biotin immunoperoxidase system. For each tumor, six different randomly selected fields were examined. The percentage of Ki-67-positive cells in the total number of cells in the five fields counted with counterstaining has been calculated. The areas of necrosis and the vascular endothelial cells when they were distinguishable were not included in the calculation. The indices determined on this material ranged from 0% to 4.5% (mean, 1.0; SD, 1.5) for 16 low grade astrocytomas; from 0.7% to 7.4% (mean, 3.5; SD, 2.2) for 8 anaplastic astrocytomas; and from 1.7% to 32.2% (mean, 11.1; SD, 8.2) for 27 glioblastomas. The differences among the means of each group are statistically significant. Five patients with malignant gliomas with an index of less than 2.5 had survival times of more than 40 weeks. These results show that the Ki-67 index of proliferating cells in human gliomas correlates with the usual histological classification of these tumors. There is a potential interest in using this technique in routine histopathology because it is simple and more rapid than the classic methods of evaluation of proliferating cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2832782     DOI: 10.1227/00006123-198802000-00015

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  35 in total

1.  The enhanced peroxidase one step method increases sensitivity for detection of Ki-67 in pituitary tumours.

Authors:  H E Turner; Z Nagy; M M Esiri; J A Wass
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

2.  Comparison of Ki-67 equivalent antibodies.

Authors:  C F Lindboe; S H Torp
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

3.  Osseous metastases from a benign intraventricular meningioma. Case report.

Authors:  W T Couldwell; H Fankhauser; N de Tribolet
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

4.  Comparison of different Ki67 antibodies in human glioblastomas.

Authors:  S H Torp; E Johannesen; C F Lindboe
Journal:  Clin Mol Pathol       Date:  1995-08

5.  Cellular and tumoural heterogeneity of EGFR gene amplification in human malignant gliomas.

Authors:  K Strommer; M F Hamou; H Diggelmann; N de Tribolet
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

Review 6.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

7.  Proliferating cell nuclear antigen expression in central nervous system neoplasms.

Authors:  A Allegranza; S Girlando; G L Arrigoni; S Veronese; F A Mauri; M Gambacorta; B Pollo; P Dalla Palma; M Barbareschi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

8.  Enhanced apoptosis in pilocytic astrocytoma: a comparative study of apoptosis and proliferation in astrocytic tumors.

Authors:  Akira Nakamizo; Takanori Inamura; Kiyonobu Ikezaki; Koji Yoshimoto; Satoshi Inoha; Masahiro Mizoguchi; Toshiyuki Amano; Masashi Fukui
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

Review 9.  Techniques to assess the proliferative potential of brain tumors.

Authors:  Alfredo Quiñones-Hinojosa; Nader Sanai; Justin S Smith; Michael W McDermott
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

10.  Proliferating cell nuclear antigen immunoreactivity in human central nervous system neoplasms.

Authors:  E Karamitopoulou; E Perentes; M Melachrinou; T Maraziotis
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.